Fig. 3

Association of the DC activation ability of BCP with the severity of implantation trauma. a Immunofluorescence staining of MHC-II, CD83, CD86 (green), and nuclei (blue). b, c Flow cytometry and semiquantification of DC activation markers CD80 and CD86 (n = 3). DCs were cultured with PBS-treated BCP, MW-BCP, or LW-BCP for 24 h